Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04703192 Active, not recruiting - Clinical trials for Relapsed/Refractory Peripheral T-Cell Lymphoma

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Start date: June 3, 2021
Phase: Phase 2
Study type: Interventional

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.

NCT ID: NCT04702503 Completed - Clinical trials for Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

Start date: March 8, 2019
Phase: Phase 1
Study type: Interventional

Single center, pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)

NCT ID: NCT04702425 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Start date: June 23, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death. Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.

NCT ID: NCT04701554 Completed - Lymphoma Clinical Trials

EFFECT OF A 16-SESSION QIGONG PROGRAM ON PHYSICAL AND MENTAL HEALTH IN PATIENTS WITH LYMPHOMA: A RANDOMIZED CONTROLLED TRIAL

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

The aim of the present study was to investigate in lymphoma patients the effects of a 16-session qigong programme (2 times a week) on physical and psychological parameters.

NCT ID: NCT04699461 Terminated - Clinical trials for Refractory Follicular Lymphoma

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

LOTIS-6
Start date: November 4, 2021
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.

NCT ID: NCT04698616 Recruiting - Malignant Lymphoma Clinical Trials

Lean Body Mass and Side Effects in Patients With Lymphoma

Start date: February 9, 2020
Phase:
Study type: Observational

The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.

NCT ID: NCT04697940 Recruiting - Clinical trials for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Start date: December 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma. A total of 19 to 33 patients are planned to be enrolled and receive decitabine-primed tandem CART 19/20 cell infusion. Phase 1 (9 to 18 cases) is dose escalation part, and phase 2 (10 to 15 cases) is expansion cohort part.

NCT ID: NCT04697290 Suspended - Clinical trials for B-cell Non-Hodgkin's Lymphoma

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.

NCT ID: NCT04697160 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

RE-MIND2
Start date: April 1, 2020
Phase:
Study type: Observational

To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.

NCT ID: NCT04696705 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

Start date: December 31, 2020
Phase: Early Phase 1
Study type: Interventional

This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL) or peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.